Advertisement
Screener

Allarity Therapeutics, Inc. (ALLR) Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature

0.8 / 5 stars · 3/18 Roast Me

Allarity Therapeutics, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature

Allarity Therapeutics, Inc. (ALLR) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $1.06 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.

Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2025-03-31

  • Allarity Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2023 was $1.06M, a 10.69% increase from fiscal 2022.
  • Allarity Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2022 was $954.00K.
Period endAdjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month
2023-12-31$1.06M
10-K · filed 2025-03-31
2022-12-31$954.00K
10-K · filed 2024-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Rocket One Inc. (RKTO)United States$0.019B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B